Mid-gut NETs respond to targeted radionuclide therapy: NETTER-1 results from nets results Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Ruszniewski talks to ecancertv at ECC 2015 about how patients with advanced gastrointestinal neuroendocrine tumours (NETs) in the mid gut have limited treatment options and there are few oncologists who are specialised in this relatively rare disease.nnHe then talks about the results of the NETTER-1 trial, which have shown that the radiolabeled somatostatin analogue 177Lutetium-DOTATATE can prolong progression-free survival for longer than octreotide LAR in these patients.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)